Close Menu

Nitto Denko

NEW YORK (GenomeWeb) – Japan's Nitto Denko announced this month that it has initiated a Phase Ib study of its siRNA-based fibrosis treatment ND-L02-s0201, just months after the drug successfully completed a Phase Ia safety study in healthy volunteers.

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

Title: Drug Carrier and Drug Carrier Kit for Inhibiting Fibrosis
Patent Number: 8,652,526
Filed: April 4, 2012

Title: Therapeutic Agent for Pulmonary Fibrosis
Patent Number: 8,574,623
Filed: Oct. 10, 2012
Lead Inventor: Yoshiro Niitsu, Nitto Denko

Title: Nucleic Acids Involved in Viral Infection
Patent Number: 8,481,506
Filed: Dec. 5, 2007
Lead Inventor: Isaac Bentwich, Rosetta Genomics

A new firm threw its hat into the RNAi therapeutics ring this week, with San Diego startup Arcturus Therapeutics announcing that it has raised $1.3 million in seed financing to advance proprietary siRNA delivery and formulation technologies into in vivo proof-of-concept

Roughly three years after partnering with Quark Pharmaceuticals to develop siRNA-based treatments for fibrotic diseases, Japan’s Nitto Denko has initiated its first clinical trial of an RNAi drug.

Title: microRNA Expression in Human Peripheral Blood Microvesicles and Uses Thereof
Patent Number: 8,455,199
Filed: Sept. 12, 2008
Lead Inventor: Clay Marsh, Ohio State University

Title: Modified Dicer Polypeptide and Methods of Use Thereof
Patent Number: 8,440,430
Filed: March 18, 2009
Lead Inventor: Jennifer Doudna, University of California, Oakland

Title: Means for Inhibiting the Expression of Protein Kinase 3
Patent Number: 8,232,256
Filed: July 20, 2007
Lead Inventor: Jorg Kaufmann, Silence Therapeutics

Pages

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.